<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174030</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18161</org_study_id>
    <nct_id>NCT01174030</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea</brief_title>
  <official_title>A 4-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Investigating the Efficacy and Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily (QD), and CD07805/47 Gel 0.18% Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this vehicle controlled study is to evaluate the efficacy and safety of
      CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18%
      applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate
      to severe facial erythema associated with rosacea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Success</measure>
    <time_frame>Day 29</time_frame>
    <description>Composite success defined as 2-grade improvement on Clinician Erythema Assessment (CEA)and Patient Self Assessment-5 (PSA-5).
Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CEA Success</measure>
    <time_frame>Day 29</time_frame>
    <description>CEA success defined as 2-grade improvement on CEA.
Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.
Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema
/ Amost clear; slight redness
/ Mild erythema; definite redness
/ Moderate erythema; marked redness
/ Severe erythema; fiery redness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA-5 Success</measure>
    <time_frame>day 29</time_frame>
    <description>Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.
PSA-5 success defined as 2-grade improvement on PSA-5.
Patient Self Assessment - 5 (PSA-5) - Grade/description 0 / No redness
/ Very mild redness
/ Mild redness
/ Moderate redness
/ Severe redness</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>CD07805/47 Gel 0.5% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07805/47 Gel 0.18% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07805/47 Gel 0.18% BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07805/47 Gel</intervention_name>
    <description>CD07805/47 Gel 0.5% QD</description>
    <arm_group_label>CD07805/47 Gel 0.5% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Gel</intervention_name>
    <description>Vehicle Gel QD</description>
    <arm_group_label>Vehicle Gel QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07805/47 Gel</intervention_name>
    <description>CD07805/47 Gel 0.18% QD</description>
    <arm_group_label>CD07805/47 Gel 0.18% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07805/47 Gel</intervention_name>
    <description>CD07805/47 Gel 0.18% BID</description>
    <arm_group_label>CD07805/47 Gel 0.18% BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Gel</intervention_name>
    <description>Vehicle Gel BID</description>
    <arm_group_label>Vehicle Gel BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, who is at least 18 years of age or older.

          -  A clinical diagnosis of rosacea.

          -  A Clinician Erythema Assessment (CEA) score of 3 at Screening and at Pre-dose (T0) on
             Baseline/Day 1.

          -  A Patient Self Assessment-5 (PSA-5) score of 3 at Screening and at Pre-dose (T0) on
             Baseline/Day 1.

          -  A Patient Self Assessment-11 (PSA-11) score of 5 at Screening and at Pre-dose (T0) on
             Baseline/Day 1.

        Exclusion Criteria:

          -  Three (3) or more facial inflammatory lesions.

          -  Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic
             hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal
             or hepatic impairment, scleroderma, Sj√∂gren's syndrome, or depression.

          -  Known allergies or sensitivities to any components of the study medications, including
             the active gel ingredient, brimonidine tartrate.

          -  Intraocular pressure (IOP) measurement less than 10 mm Hg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Graeber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma R&amp;D, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Abramovits, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Treatment &amp; Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fran Cook-Bolden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Specialty Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zoe Draelos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Consulting Services, High Point NC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Specialists, PSC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kimberly Grande, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Skin Wellness Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Heffernan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Dermatology PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kempers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Clinical Study Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Ling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meda Phase, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Matheson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kappa Meadows, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Education &amp; Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arlington Center for Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Girish Munavalli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology, Laser &amp; Vein Specialists of the Carolinas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Pollack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philadelphia Institute of Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phoebe Rich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Dermatology &amp; Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry Sharta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Madison Skin &amp; Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Steinhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California at San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dow Stough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Burke Pharmaceutical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Werschler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premier Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Westmoreland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palmetto Clinical Trial Services, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Schleicher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DermDox</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meda Phase, Inc</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists PC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology, PC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialty Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Laser &amp; Vein Specialists</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology &amp; Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Institute of Dermatology</name>
      <address>
        <city>Fort Washington</city>
        <state>Pennsylvania</state>
        <zip>19034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermDox</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Wellness Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Center for Dermatology</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Treatment &amp; Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education &amp; Research Foundation</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madison Skin &amp; Research</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2010</study_first_posted>
  <results_first_submitted>September 19, 2013</results_first_submitted>
  <results_first_submitted_qc>January 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2014</results_first_posted>
  <disposition_first_submitted>June 6, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 6, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 16, 2011</disposition_first_posted>
  <last_update_submitted>January 24, 2014</last_update_submitted>
  <last_update_submitted_qc>January 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CD07805/47 Gel 0.5% QD</title>
          <description>CD07805/47 Gel 0.5% Once Daily</description>
        </group>
        <group group_id="P2">
          <title>CD07805/47 Gel 0.18% QD</title>
          <description>CD07805/47 Gel 0.18% Once Daily</description>
        </group>
        <group group_id="P3">
          <title>CD07805/47 Gel 0.18% BID</title>
          <description>CD07805/47 Gel 0.18% Twice Daily</description>
        </group>
        <group group_id="P4">
          <title>Vehicle Gel QD</title>
          <description>Vehicle Gel Once Daily</description>
        </group>
        <group group_id="P5">
          <title>Vehicle Gel BID</title>
          <description>Vehicle Gel Twice Daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CD07805/47 Gel 0.5% QD</title>
        </group>
        <group group_id="B2">
          <title>CD07805/47 Gel 0.18% QD</title>
        </group>
        <group group_id="B3">
          <title>CD07805/47 Gel 0.18% BID</title>
        </group>
        <group group_id="B4">
          <title>Vehicle Gel QD</title>
        </group>
        <group group_id="B5">
          <title>Vehicle Gel BID</title>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="54"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="53"/>
            <count group_id="B6" value="269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" spread="11.50"/>
                    <measurement group_id="B2" value="46.9" spread="12.72"/>
                    <measurement group_id="B3" value="43.2" spread="12.28"/>
                    <measurement group_id="B4" value="43.4" spread="12.73"/>
                    <measurement group_id="B5" value="43.0" spread="12.33"/>
                    <measurement group_id="B6" value="44.3" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Success</title>
        <description>Composite success defined as 2-grade improvement on Clinician Erythema Assessment (CEA)and Patient Self Assessment-5 (PSA-5).
Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.</description>
        <time_frame>Day 29</time_frame>
        <population>Intent-to Treat (ITT) population, LOCF when the data are missing at all four timepoints (i.e. Hours 3, 6, 9, 12) LOCF method will be applied from previous visit.</population>
        <group_list>
          <group group_id="O1">
            <title>CD07805/47 Gel 0.5% QD</title>
          </group>
          <group group_id="O2">
            <title>CD07805/47 Gel 0.18% QD</title>
          </group>
          <group group_id="O3">
            <title>CD07805/47 Gel 0.18% BID</title>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel QD</title>
          </group>
          <group group_id="O5">
            <title>Vehicle Gel BID</title>
          </group>
        </group_list>
        <measure>
          <title>Composite Success</title>
          <description>Composite success defined as 2-grade improvement on Clinician Erythema Assessment (CEA)and Patient Self Assessment-5 (PSA-5).
Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.</description>
          <population>Intent-to Treat (ITT) population, LOCF when the data are missing at all four timepoints (i.e. Hours 3, 6, 9, 12) LOCF method will be applied from previous visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29/Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>GEE:Logit link function</method>
            <method_desc>Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.392</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.637</ci_lower_limit>
            <ci_upper_limit>26.710</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.549</p_value>
            <method>GEE:Logit link function</method>
            <method_desc>Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.269</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.586</ci_lower_limit>
            <ci_upper_limit>2.747</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>GEE:Logit link function</method>
            <method_desc>Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.738</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.097</ci_lower_limit>
            <ci_upper_limit>12.742</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CEA Success</title>
        <description>CEA success defined as 2-grade improvement on CEA.
Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.
Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema
/ Amost clear; slight redness
/ Mild erythema; definite redness
/ Moderate erythema; marked redness
/ Severe erythema; fiery redness</description>
        <time_frame>Day 29</time_frame>
        <population>ITT population, LOCF when the data are missing at all four timepoints (i.e. Hours 3,6,9,12) LOCF method will be applied from the previous visit.</population>
        <group_list>
          <group group_id="O1">
            <title>CD07805/47 Gel 0.5% QD</title>
          </group>
          <group group_id="O2">
            <title>CD07805/47 Gel 0.18% QD</title>
          </group>
          <group group_id="O3">
            <title>CD07805/47 Gel 0.18% BID</title>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel QD</title>
          </group>
          <group group_id="O5">
            <title>Vehicle Gel BID</title>
          </group>
        </group_list>
        <measure>
          <title>CEA Success</title>
          <description>CEA success defined as 2-grade improvement on CEA.
Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.
Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema
/ Amost clear; slight redness
/ Mild erythema; definite redness
/ Moderate erythema; marked redness
/ Severe erythema; fiery redness</description>
          <population>ITT population, LOCF when the data are missing at all four timepoints (i.e. Hours 3,6,9,12) LOCF method will be applied from the previous visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29/Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.003</p_value>
            <method>GEE:Logit link Function</method>
            <method_desc>Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.683</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.388</ci_lower_limit>
            <ci_upper_limit>5.188</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>GEE: Logit link Function</method>
            <method_desc>Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.892</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.980</ci_lower_limit>
            <ci_upper_limit>3.651</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>GEE:Logit link Function</method>
            <method_desc>Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.885</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.946</ci_lower_limit>
            <ci_upper_limit>3.756</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PSA-5 Success</title>
        <description>Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.
PSA-5 success defined as 2-grade improvement on PSA-5.
Patient Self Assessment - 5 (PSA-5) - Grade/description 0 / No redness
/ Very mild redness
/ Mild redness
/ Moderate redness
/ Severe redness</description>
        <time_frame>day 29</time_frame>
        <population>ITT population, LOCF when the data are missing at all four timepoints (i.e. Hours 3,6,9,12) LOCF method will be applied from the previous visit.</population>
        <group_list>
          <group group_id="O1">
            <title>CD07805/47 Gel 0.5% QD</title>
          </group>
          <group group_id="O2">
            <title>CD07805/47 Gel 0.18% QD</title>
          </group>
          <group group_id="O3">
            <title>CD07805/47 Gel 0.18% BID</title>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel QD</title>
          </group>
          <group group_id="O5">
            <title>Vehicle Gel BID</title>
          </group>
        </group_list>
        <measure>
          <title>PSA-5 Success</title>
          <description>Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.
PSA-5 success defined as 2-grade improvement on PSA-5.
Patient Self Assessment - 5 (PSA-5) - Grade/description 0 / No redness
/ Very mild redness
/ Mild redness
/ Moderate redness
/ Severe redness</description>
          <population>ITT population, LOCF when the data are missing at all four timepoints (i.e. Hours 3,6,9,12) LOCF method will be applied from the previous visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29/Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>GEE: Logit link function</method>
            <method_desc>Generalize Estimating Equation (GEE) methods with Logit link function and marginal expectation model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.582</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.755</ci_lower_limit>
            <ci_upper_limit>15.723</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.093</p_value>
            <method>GEE: Logit link function</method>
            <method_desc>Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.853</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.903</ci_lower_limit>
            <ci_upper_limit>3.802</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>GEE: Logit link function</method>
            <method_desc>Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.365</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.960</ci_lower_limit>
            <ci_upper_limit>5.825</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CD07805/47 Gel 0.5% QD</title>
        </group>
        <group group_id="E2">
          <title>CD07805/47 Gel 0.18% QD</title>
        </group>
        <group group_id="E3">
          <title>CD07805/47 Gel 0.18% BID</title>
        </group>
        <group group_id="E4">
          <title>Vehicle Gel QD</title>
        </group>
        <group group_id="E5">
          <title>Vehicle Gel BID</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Skin Burning Sensation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Skin Warm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Graeber, MD</name_or_title>
      <organization>Galderma</organization>
      <phone>609-860-8201</phone>
      <email>michael.graeber@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

